Follitropin
FDA approved · RxRecombinant gonadotropin hormone
Also known as: Gonal-f, Follistim, FSH, Follistim Aq, Gonal-F, Gonal-F Rff Redi-Ject
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 387 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Follitropin is a lab-made (recombinant) version of follicle-stimulating hormone, a glycoprotein hormone normally released by the pituitary gland. It binds FSH receptors in the ovaries and testes, where it supports the growth of ovarian follicles in women and sperm production in men. It is sold under brand names including Gonal-f and Follistim AQ.
What the evidence shows
Follitropin is FDA-approved as a prescription medicine for inducing ovulation and developing multiple follicles in assisted reproduction, and for inducing sperm production in certain men with hypogonadotropic hypogonadism. Its use is supported by a large body of human research, with 384 registered trials reaching Phase 4 and over 800 published papers, though uses outside approved indications are less established.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Study on the Safety and Pharmacokinetics of LM001 and Gonal-F® in Healthy Women
Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)
A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)
A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
A molecular dissection of the glycoprotein hormone receptors.
Co-evolution of ligand-receptor pairs.
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.